Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period
Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent b...
Saved in:
Published in | Cancer research and treatment Vol. 55; no. 1; pp. 258 - 269 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Korean Cancer Association
01.01.2023
대한암학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1598-2998 2005-9256 2005-9256 |
DOI | 10.4143/crt.2022.418 |
Cover
Abstract | Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities. |
---|---|
AbstractList | Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities. KCI Citation Count: 0 This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.PURPOSEThis study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.MATERIALS AND METHODSMedical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.RESULTSThe median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.CONCLUSIONIGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities. This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period. Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses. The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity. IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities. Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities. |
Author | Park, Noh Hyun Lee, Maria Lee, Tae Hoon Chung, Hyun Hoon Kang, Seonghee Kim, Jae-Weon Wee, Chan Woo Song, Yong Sang Kang, Hyun-Cheol Kim, Hak Jae Kim, Kyung Su Choi, Chang Heon Kim, Hee Seung Eom, Keun-Yong |
AuthorAffiliation | 2 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea 4 Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea 1 Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea 3 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea 6 Department of Radiation Oncology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea 7 Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea 5 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea |
AuthorAffiliation_xml | – name: 3 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea – name: 4 Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea – name: 5 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea – name: 2 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea – name: 6 Department of Radiation Oncology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea – name: 1 Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea – name: 7 Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Tae Hoon surname: Lee fullname: Lee, Tae Hoon – sequence: 2 givenname: Kyung Su surname: Kim fullname: Kim, Kyung Su – sequence: 3 givenname: Hak Jae surname: Kim fullname: Kim, Hak Jae – sequence: 4 givenname: Chang Heon surname: Choi fullname: Choi, Chang Heon – sequence: 5 givenname: Seonghee surname: Kang fullname: Kang, Seonghee – sequence: 6 givenname: Keun-Yong surname: Eom fullname: Eom, Keun-Yong – sequence: 7 givenname: Chan Woo surname: Wee fullname: Wee, Chan Woo – sequence: 8 givenname: Yong Sang surname: Song fullname: Song, Yong Sang – sequence: 9 givenname: Noh Hyun surname: Park fullname: Park, Noh Hyun – sequence: 10 givenname: Jae-Weon surname: Kim fullname: Kim, Jae-Weon – sequence: 11 givenname: Hyun Hoon surname: Chung fullname: Chung, Hyun Hoon – sequence: 12 givenname: Hee Seung surname: Kim fullname: Kim, Hee Seung – sequence: 13 givenname: Maria surname: Lee fullname: Lee, Maria – sequence: 14 givenname: Hyun-Cheol surname: Kang fullname: Kang, Hyun-Cheol |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35952716$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002923313$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNptUktvEzEQtlARTQs3zshHhNiy9r5sDkhhVUqkSCAauFqOH4nprh3s3UD-DT-V2aZFgDiNPs_3GI3nDJ344A1CT0l-UZKyeKXicEFzSgGxB2hG87zKOK3qEzQjFWcZ5ZydorOUvuZ5XRYNeYROi4pXtCH1DP1c9HJjsqvRaaPxFxPTmHAb_N74wQUvO_w2SrU9DFsT5e6AbYh4GZTsugOe6730CmStiXsHb7idcHyNL3_sTHQGAA4WXzu_6Qxe-DS4YZxs8Xc3bDF44mvZG_wRIqAFDROx9Bqv3PQKFkE_Rg-t7JJ5clfP0ed3l6v2fbb8cLVo58tMlYQPWWM5LyorK6Z1RbnUNaW0oQWz1JCyYUxLu7YVKUtO6pzkimtty9LytdJrzeviHL04-vpoxY1yIkh3WzdB3EQx_7RaCALChhIC5DdH8m5c90YrWFaUndhF18t4uJX-3fFuC0Z7wVlTFJSBwfM7gxi-jSYNondJma6T3oQxCdrklLCmptNgz_7M-h1y_4dAoEeCiiGlaKxQbpDTNiHadTC1mA5FwKGI6VAATQO8_Ed07_tf-i_338Jk |
CitedBy_id | crossref_primary_10_1007_s40278_023_35265_1 crossref_primary_10_3390_healthcare11152187 |
Cites_doi | 10.3802/jgo.2016.27.e33 10.1016/j.ygyno.2020.03.006 10.1016/j.radonc.2009.06.032 10.5114/jcb.2018.73955 10.1016/j.radonc.2011.08.014 10.1016/j.radonc.2016.06.006 10.1016/j.brachy.2017.05.001 10.3109/0284186x.2013.818253 10.1016/j.radonc.2021.01.019 10.1016/j.brachy.2018.04.005 10.1016/j.ygyno.2014.08.027 10.1136/ijgc-2019-001135 10.1016/j.radonc.2004.12.015 10.1093/jrr/rrv047 10.1016/j.brachy.2021.03.004 10.1016/j.ijrobp.2013.05.033 10.1007/s00066-020-01658-0 10.1016/j.ijrobp.2010.12.029 10.1186/s13014-021-01877-4 10.1016/j.brachy.2011.07.002 10.1097/igc.0000000000000883 10.1016/j.ijrobp.2009.10.075 10.1016/j.ygyno.2015.02.025 10.3346/jkms.2018.33.e135 10.1016/j.radonc.2016.03.011 10.1016/j.ijrobp.2018.11.012 10.1016/s0167-8140(03)00189-0 10.1016/s1470-2045(12)70011-6 |
ContentType | Journal Article |
Copyright | Copyright © 2023 by the Korean Cancer Association 2023 |
Copyright_xml | – notice: Copyright © 2023 by the Korean Cancer Association 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.4143/crt.2022.418 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2005-9256 |
EndPage | 269 |
ExternalDocumentID | oai_kci_go_kr_ARTI_10107211 PMC9873328 35952716 10_4143_crt_2022_418 |
Genre | Journal Article |
GroupedDBID | --- 29B 5-W 53G 8JR 9ZL AAYXX ABDBF ACUHS ACYCR ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. F5P HYE OK1 RPM TR2 C1A CGR CUY CVF ECM EIF NPM 7X8 5PM M~E |
ID | FETCH-LOGICAL-c419t-7f9935fa58dd529ad62227238f2e14788dafbf5144916010c9ddf44f9bcdbd963 |
ISSN | 1598-2998 2005-9256 |
IngestDate | Sat Apr 06 03:24:31 EDT 2024 Thu Aug 21 18:38:13 EDT 2025 Thu Jul 10 22:46:09 EDT 2025 Thu Apr 03 07:09:56 EDT 2025 Thu Apr 24 23:10:15 EDT 2025 Tue Jul 01 03:18:51 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Uterine cervical neoplasms Brachytherapy Sigmoid colon Three-dimensional imaging Rectum |
Language | English |
License | This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c419t-7f9935fa58dd529ad62227238f2e14788dafbf5144916010c9ddf44f9bcdbd963 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-8981-6123 0000-0002-4723-3931 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9873328 |
PMID | 35952716 |
PQID | 2702187626 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10107211 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9873328 proquest_miscellaneous_2702187626 pubmed_primary_35952716 crossref_citationtrail_10_4143_crt_2022_418 crossref_primary_10_4143_crt_2022_418 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-01-01 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Cancer research and treatment |
PublicationTitleAlternate | Cancer Res Treat |
PublicationYear | 2023 |
Publisher | Korean Cancer Association 대한암학회 |
Publisher_xml | – name: Korean Cancer Association – name: 대한암학회 |
References | ref12 ref14 ref31 ref11 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 (ref13) 1985 Kemp (ref30) c2022 ref24 ref23 ref26 ref25 Potter (ref4) 2021 ref20 ref22 ref21 ref28 ref27 (ref15) c2017 ref29 ref8 ref7 ref9 ref3 ref6 ref5 |
References_xml | – ident: ref6 doi: 10.3802/jgo.2016.27.e33 – start-page: 538 volume-title: MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study year: 2021 ident: ref4 – ident: ref32 doi: 10.1016/j.ygyno.2020.03.006 – ident: ref26 doi: 10.1016/j.radonc.2009.06.032 – ident: ref10 doi: 10.5114/jcb.2018.73955 – ident: ref31 doi: 10.1016/j.radonc.2011.08.014 – ident: ref22 doi: 10.1016/j.radonc.2016.06.006 – volume-title: Update on CALLA Phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally advanced cervical cancer [Internet] year: c2022 ident: ref30 – ident: ref9 doi: 10.1016/j.brachy.2017.05.001 – ident: ref18 doi: 10.3109/0284186x.2013.818253 – ident: ref24 doi: 10.1016/j.radonc.2021.01.019 – ident: ref27 doi: 10.1016/j.brachy.2018.04.005 – ident: ref8 doi: 10.1016/j.ygyno.2014.08.027 – volume-title: Dose and volume specification for reporting intracavitary therapy in gynaecology year: 1985 ident: ref13 – ident: ref12 doi: 10.1136/ijgc-2019-001135 – ident: ref14 doi: 10.1016/j.radonc.2004.12.015 – ident: ref5 doi: 10.1093/jrr/rrv047 – ident: ref17 doi: 10.1016/j.brachy.2021.03.004 – ident: ref1 doi: 10.1016/j.ijrobp.2013.05.033 – ident: ref16 doi: 10.1007/s00066-020-01658-0 – ident: ref23 doi: 10.1016/j.ijrobp.2010.12.029 – ident: ref2 doi: 10.1186/s13014-021-01877-4 – ident: ref21 doi: 10.1016/j.brachy.2011.07.002 – ident: ref28 doi: 10.1097/igc.0000000000000883 – ident: ref11 doi: 10.1016/j.ijrobp.2009.10.075 – ident: ref3 doi: 10.1016/j.ygyno.2015.02.025 – ident: ref7 doi: 10.3346/jkms.2018.33.e135 – ident: ref20 doi: 10.1016/j.radonc.2016.03.011 – volume-title: Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet] year: c2017 ident: ref15 – ident: ref19 doi: 10.1016/j.ijrobp.2018.11.012 – ident: ref25 doi: 10.1016/s0167-8140(03)00189-0 – ident: ref29 doi: 10.1016/s1470-2045(12)70011-6 |
SSID | ssj0064371 |
Score | 2.264786 |
Snippet | Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT)... This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT)... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 258 |
SubjectTerms | Brachytherapy - adverse effects Female Gastrointestinal Diseases - etiology Humans Original Radiotherapy Dosage Rectum Retrospective Studies Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - radiotherapy 의학일반 |
Title | Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35952716 https://www.proquest.com/docview/2702187626 https://pubmed.ncbi.nlm.nih.gov/PMC9873328 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002923313 |
Volume | 55 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Cancer Research and Treatment, 2023, 55(1), , pp.258-269 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa6TZr2griv3GQEPFWB2kmamre2MLrBeGGT9hYljk2rXjKV5qH8Gh75mZxjO2lSbRLwktaJa0s9X-xj-zvfIeS1FNL3BePwirPEC5gWXp9HGAUcZjzlXSFNFoXzr73xZXB2FV61Wr9rrKVinb6VP2-MK_kfq8I9sCtGyf6DZatG4QZ8B_vCFSwM17-y8ekCRgPvUzHNwG3Ena_CZODc0siHq0RONjbGyjIzv-DcNd90BuXZ_8gMFriFgGWTNHIrf2xCWmBym6uKVYBwsZu3ALBvyUI1JI_MWQSGlSC1fpo3soDaDjpOXshG1FU89x1i0EWiOuO8ThEwuP28KVBAvNi5PU5mnbOkguhokk8dlQBqj5Vrxu1tcL-2t6HMGGiEUgW32uPlgG11fRvAdKOvVYHfnRUC8AnBlHKF3FnOodyoBn_s9cIgBIOUecR2pLntZO8e7ZEDHkVICDgYDD8MT8pZH88_mQ2swO7e1Ts7Ioflzxvez95ypW9a2Ozyc2sOz8VdcsetVOjAwu4eaanlfXJ47rgYD8ivOvqoRR-to4820EcBfdShj5booyX6qAXHe7rFHs01tdijNexRxB6FNilij9axRwFQFLFHLfYeksuTjxejsefyfXgyYGLtRRqc5VAnYT_LQi6SrIeB2uBTaq4YpnnIEp1q8PADWNN0WVeKLNNBoEUqszSDmeQR2V9Cf8eEMulH2lc-ih0F3UilIk2QYyFCIWWgZZt0SjvE0onhY06WeQyLYjRgDAaM0YBQ6rfJm6r2tRWBuaXeKzBpPJPTGFXb8fN7Hs9WMaxNT5FMiWKErE1eliaPYSzHA7pkqfLiR4yxoQzdk16bPLYQqPorEdQmUQMcVQXssflkOZ0YvXjRj3yf95_c2uZTcrR9-56R_fWqUM_B116nLxzM_wAv3NnD |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Image-Guided+Versus+Conventional+Brachytherapy+for+Locally+Advanced+Cervical+Cancer%3A+Experience+of+Single+Institution+with+the+Same+Practitioner+and+Time+Period&rft.jtitle=Cancer+research+and+treatment&rft.au=Lee%2C+Tae+Hoon&rft.au=Kim%2C+Kyung+Su&rft.au=Kim%2C+Hak+Jae&rft.au=Choi%2C+Chang+Heon&rft.date=2023-01-01&rft.eissn=2005-9256&rft.volume=55&rft.issue=1&rft.spage=258&rft_id=info:doi/10.4143%2Fcrt.2022.418&rft_id=info%3Apmid%2F35952716&rft.externalDocID=35952716 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon |